| Literature DB >> 32065510 |
Catherine Connolly1, Stefan Stättner1, Thomas Niederwieser1, Florian Primavesi1.
Abstract
Lactate measurements have proven utility as a triage tool, therapeutic guide, and prognostic indicator, with broad use in Acute Care and transplantation. Its value in guiding therapy and predicting outcomes following liver resection is less well-defined. This systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines assessed the relationship between peri-operative lactate levels and morbidity and mortality after liver resection. Seven relevant studies comprising 2573 patients in total were identified. Six studies assessed intra-operative or early postoperative lactate levels, one publication examined pre-operative levels. All studies demonstrated a significant association between peri-operative lactate levels and adverse outcomes. The influence of pre-operative diabetes and cirrhosis on postoperative lactate levels was shown in one study each, no study assessed the association of lactate with post-hepatectomy liver failure according to defined criteria. The heterogeneity of study measurements and end-points precluded a meta-analysis from being performed. Early postoperative lactate >3-3.7 mmol/L is associated with mortality but validation of clear cut-off levels for outcome prediction is pending. Literature suggests lactate is a useful predictive marker for outcomes post liver surgery, especially when measured in the early postoperative phase. Further research is required to standardize the use of lactate measurements in a meaningful therapeutic manner.Entities:
Keywords: complications; lactate; liver failure; liver resection; outcome
Mesh:
Substances:
Year: 2020 PMID: 32065510 PMCID: PMC7496457 DOI: 10.1002/jhbp.727
Source DB: PubMed Journal: J Hepatobiliary Pancreat Sci ISSN: 1868-6974 Impact factor: 7.027
Figure 1Search strategy applied for the systematic review (A) and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) diagram showing selection of resulting publications (B)
Characteristics of included studies
| Study | Country | Design | Sample size | Procedures | Operative diagnoses | Time of lactate measurement | Outcomes measured | Follow‐up |
|---|---|---|---|---|---|---|---|---|
| Watanabe et al (2007) | Japan | Retrospective cohort | 151 | Liver resections | — | Postoperative (Day 0) | Mortality; morbidity; length of stay; peak bilirubin | Duration of admission |
| Wiggans et al (2013) | United Kingdom | Retrospective cohort | 488 | Liver resections |
Benign: 8.2% Primary malignancy: 20.7% Secondary malignancy: 71.1% | Postoperative (Day 0) | Mortality; renal dysfunction; peak bilirubin & prothrombin time; length of stay | 90 d |
| Meguro et al (2014) | Japan | Prospective cohort | 77 | Liver resections |
Benign: n.a. Primary malignancy: 63.6% Secondary malignancy: 36.3% | Intra‐operative (highest level) | Wound or intra‐abdominal infections | Duration of admission |
| Riediger et al (2014) | Germany | Prospective cohort | 337 | Open liver resections |
Benign: 20.8% Primary malignancy: 32% Secondary malignancy: 45.7% Liver trauma: 1.5% | Pre‐operative (Day 0) | Mortality; morbidity; re‐operation | 30 d |
| Pagano et al (2015) | Italy | Retrospective cohort | 45 | Extended hepatectomies |
Benign: 8.9% Primary malignancy: 33.3% Secondary malignancy: 53.4% Liver trauma: 4.4% | Postoperative (Day 0 and Day 5) | Mortality; morbidity; length of stay | 90 d |
| Vibert et al (2015) | France | Prospective cohort |
519—TC 466—VC | Liver resections |
Benign: 10.3% Primary malignancy: 42.2% Secondary malignancy: 45.2% Parasitosis: 2.1% | Postoperative (Day 0, 1‐4 h postoperative) | Comprehensive complication index; mortality; morbidity | 90 d |
| Lemke et al (2017) | Canada | Retrospective cohort | 490 | Liver resection |
Benign: 10.2% Primary malignancy: 12% Secondary malignancy: 73.4% NET: 4.3% | Postoperative (Day 0) | Mortality; morbidity; length of stay | 90 d |
Abbreviations: n.a., data not available; NET, neuroendocrine tumours; TC, training cohort; VC, validation cohort.
Methodological assessment
| Study | Oxford level of evidence | Representativeness of exposed cohort | Selection of non‐exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Assessment of outcome | Follow‐up duration | Follow‐up complete |
|---|---|---|---|---|---|---|---|---|
| Watanabe et al (2007) | 2b |
| — |
| — |
|
|
|
| Wiggans et al (2013) | 2b |
| — |
| — |
|
|
|
| Meguro et al (2014) | 2b |
|
|
| — |
|
|
|
| Riediger et al (2014) | 2b |
| — |
| — |
|
|
|
| Pagano et al (2015) | 2b |
| — |
| — |
|
|
|
| Vibert et al (2015) | 2b |
| — |
| — |
|
|
|
| Lemke et al (2017) | 2b |
|
|
| — |
|
|
|
, consistent with Newcastle‐Ottawa criteria; , partly consistent with Newcastle‐Ottawa criteria; , not consistent with Newcastle‐Ottawa criteria; —, not applicable.
Outcomes
| Study | Mortality | Morbidity | Other outcomes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall rate | Median lactate level with/without event (mmol/L) | Lactate cut‐off (mmol/L)/AUC for prediction of event | Regression/ROC analysis | Overall rate | Median lactate level with/without event (mmol/L) | Lactate cut‐off (mmol/L)/AUC for prediction of event | Regression/ROC analysis | Length of stay: median (range) | Lactate association with: peak bilirubin/prothrombin time | |
| Watanabe et al (2007) | 6.6% | 10.1/4.1 ( | AUC 0.86 ( | Multivariable: Lactate | 45% | 5.5/3.6 ( | — | Multivariable: Lactate |
30 (range n.a.) ICU‐stay: |
Bilirubin
|
| Wiggans et al (2013) | 4.7% | — | — | Univariable: 0.373 ± 0.079 (coeff. ± SD; | 7% | — |
<2.0: 2.2% >6.0: 27.5% | Univariable: renal dysfunction 0.324 ± 0.072 (coeff. ± SD; |
7 (2‐78) Univariable: 0.046 ± 0.006 (coeff. ± SD; |
Bilirubin: Univariable: 0.146 ± 0.017 (coeff. ± SD; Prothrombin time: Univariable: 0.055 ± 0.002 (coeff. ± SD; |
| Meguro et al (2014) | ||||||||||
| Chronic hepatitis/Liver cirrhosis group | — | — | — | — | 25% | — |
3.2 Sens.: 90.9% Spec.: 66.7% | AUC 0.831 ( | — |
Bilirubin: Prothrombin time: |
| Normal liver group | — | — | — | — | 18.2% | — |
4.8 Sens.: 66.7% Spec.: 88.9% | AUC 0.759 ( | — |
Bilirubin: Prothrombin time: |
| Riediger et al (2014) | 3.7% | Pre‐operative: 4.1/1.6 ( |
Cut‐off: 4.5 >4.5: 23.5% Mort. ≤4.5: 3% Mort. ( |
Multivariable: OR 1.47 (95%CI 1.15‐1.90) ( | 32.7% | Pre‐operative: 2.3/1.4 ( |
1.2 >1.2: 47.2% Morb. ≤1.2: 6.8% Morb.
| — | — | — |
| Pagano et al (2015) | 6.7% | 8.5/4.5 ( | — | — | 48.9% (CD III‐IV) | 5.5/3.7 ( | — |
Multivariable: OR 5.1 (95% CI: 1.1‐22) ( | 11 (5‐107) | — |
| Vibert et al (2015) | 4.1% | — |
Cut‐off: 3.0 AUC 0.87 (training cohort) | Multivariable: OR 2.34 (95%CI 1.21‐5.39; | 25.1% (CD III‐IV) | — |
2.8 AUC 0.76 |
Multivariable OR 1.96 (95%CI 1.1‐3.86; | — | |
| Lemke et al (2017) | 6.3% | — | 3.72 |
Univariable: OR 1.56 (95%CI 1.34‐1.82; Multivariable: OR 1.52 (95%CI 1.28‐1.81; | 13.5% (CD III‐IV) | — | 3.96 |
Univariable: OR 1.29 (95%CI 1.17‐1.42; Multivariable: OR 1.19 (95%CI 1.06‐1.33; |
7 (6‐12) Univariable OR 1.08 (95%CI 1.05‐1.11) Multivariable: OR 1.03 (95%CI 1.00‐1.06) | — |
Abbreviations: AUC, area under the curve; CD, Clavien‐Dindo; CI, confidence interval; coeff. coefficient; Morb., morbidity; Mort., mortality; n.a. not available; OR, odds ratio; ROC, receiver operating characteristics; SD, standard deviation; Sens., sensitivity; Spec., specificity.
Renal dysfunction only;
Infectious complications only.